Biopolis and Singapore’s Biomedical Bet: What Industrial Policy Can and Cannot Buy

Singapore decided in 2000 to build a biomedical industry, and then did. The manufacturing outcome exceeded expectations. The research outcome is a more honest and more interesting story, because it shows what industrial policy can and cannot purchase. This case study is part of the healthcare, biotech and life sciences pillar of the Singapore Company Stories hub.

Why did Singapore target biomedical sciences?

By the late 1990s the government concluded that electronics manufacturing alone could not sustain long-term growth, and identified biomedical sciences as a fourth pillar alongside electronics, chemicals and engineering.

The reasoning was that pharmaceutical and medical products have very high value per unit weight, are relatively insensitive to labour cost, require intellectual property protection and skilled workers, and face growing global demand from ageing populations.

That profile matched Singapore’s constraints almost exactly, in the same way semiconductor equipment manufacturing did, as discussed in the semiconductor case study.

What did the strategy actually involve?

The programme combined building physical research infrastructure, funding public research institutes, recruiting internationally recognised scientists with substantial packages, offering incentives for corporate research and manufacturing investment, and training local researchers.

The scientist recruitment attracted attention because it was unusually direct: Singapore identified prominent researchers and offered facilities, funding and freedom to relocate their laboratories.

It also attracted criticism, both over cost and over whether transplanted researchers would build lasting local capability or simply run their existing programmes in a new location.

Why did pharmaceutical manufacturing succeed?

Major pharmaceutical companies built plants in Singapore for active ingredients, formulation, biologics and vaccines, attracted by intellectual property protection, regulatory quality, skilled technicians, political stability and incentives.

Pharmaceutical manufacturing is process-intensive rather than labour-intensive, and regulatory approval of a specific plant for a specific product creates enormous switching costs once production is qualified.

That qualification lock-in is why pharmaceutical plants, once established, rarely relocate. It is the same dynamic that keeps complex contract manufacturing in Singapore, described in the precision manufacturing case study.

Why has commercialisation been harder?

Translating research into approved products requires clinical development capability, patient populations for trials, venture capital willing to fund decade-long timelines, and experienced management, and Singapore had limited depth in all of these.

Drug development is also a numbers game. The probability that any single research programme produces an approved product is very low, and even a well-funded ecosystem needs a large volume of shots to generate hits.

A small country cannot generate that volume domestically, which means commercialisation success depends on partnering into global networks rather than on producing champions locally.

What has the strategy actually delivered?

It delivered a substantial pharmaceutical and biologics manufacturing base, a research infrastructure that supports both public science and corporate laboratories, a trained technical workforce and credibility that attracted continued investment.

It also delivered capability that proved valuable during the pandemic, when vaccine and therapeutic manufacturing capacity and clinical research capability had immediate national significance.

What it has not delivered at scale is a domestic biotechnology industry producing its own approved therapies, which was always the most ambitious and least controllable element of the plan.

What is the outlook for the sector?

The manufacturing base continues to attract investment, particularly in biologics, cell and gene therapy production and vaccine capacity, where technical complexity favours locations with regulatory credibility.

Research emphasis has shifted toward areas where Singapore has genuine advantages, including infectious disease relevant to the region, Asian-specific genomics, medical technology and clinical translation in defined therapeutic areas.

The realistic assessment is a strong manufacturing and applied research position rather than a global biotechnology hub, which is a good outcome measured honestly and a disappointment measured against the original rhetoric. That distinction recurs across the Singapore Company Stories hub.

What does A*STAR do?

The national research agency operates public research institutes across biomedical, physical and engineering sciences, funds research, trains scientists and works with industry on translational projects.

Its dual role, conducting research and supporting industry, is deliberate, and its performance is assessed partly on industrial collaboration rather than publications alone.

Scholarship programmes sending students abroad for doctoral training and returning them to local institutions have been a central mechanism for building domestic scientific capability over time.

How did the pandemic change the sector?

The pandemic demonstrated the strategic value of domestic biomedical capability, including diagnostics development, clinical research infrastructure, vaccine manufacturing capacity and public health analytics.

It accelerated investment in vaccine and biologics manufacturing, with new facilities committed for regional supply, on the reasoning that supply security cannot depend entirely on other countries during a crisis.

It also validated the long-horizon argument for research funding, since the capabilities that proved useful had been built over two decades without a specific crisis in mind.

What is the medical technology sector like?

Singapore hosts medical device manufacturing and development, including implantable devices, diagnostics and equipment, which suits its precision engineering base and regulatory credibility.

Medical devices have shorter development cycles and lower failure rates than pharmaceuticals, which makes them a more achievable commercialisation target for a small ecosystem.

The sector connects directly to the contract manufacturing base described in the precision manufacturing case study, where regulatory qualification is the main barrier to entry.

How does the sector recruit and retain scientists?

Recruitment combines competitive packages, research funding, modern facilities and the practical advantages of living in Singapore, competing against established research centres in the United States, Europe and increasingly China.

Retention has been harder than recruitment in some cases, with several high-profile researchers departing after their initial terms, which prompted debate about whether the strategy built lasting capability.

The more durable investment has been in training local researchers through scholarship and doctoral programmes, since they are more likely to build careers and institutions locally over decades.

What is the venture funding environment for biotech?

Biotechnology venture funding in Singapore exists but is thinner than in major hubs, with government co-investment vehicles playing a significant role alongside private and corporate venture capital.

Drug development requires very large sums over very long periods, and the specialist investors willing to fund that are concentrated in a small number of global locations.

Regional biotech companies therefore frequently raise from international investors and may eventually relocate or list abroad, which limits the local ecosystem’s ability to retain successes.

What is contract development and manufacturing?

Contract development and manufacturing organisations produce drugs and biologics for other companies, providing capacity and regulatory expertise without owning the product.

This is a strong fit for Singapore because it monetises manufacturing and regulatory capability without requiring the company to discover a drug, which is the highest-risk part of the value chain.

The model parallels the semiconductor foundry logic examined in the Chartered Semiconductor case study: manufacture for others rather than compete in discovery.

What is the clinical trials position?

Singapore hosts clinical research supported by academic medical centres, a regulatory framework recognised internationally, and quality data standards, though patient recruitment scale is limited by population size.

Its strongest position is in early-phase trials and in studies where Asian patient populations are specifically relevant, since much clinical evidence historically derived from Western populations.

Regional trial networks extending into larger neighbouring populations are the practical response to the recruitment constraint, with Singapore providing coordination and quality assurance.

How does the sector connect to Singapore’s food security?

Agri-food technology, including cultivated protein, precision fermentation and controlled environment agriculture, draws on the same biological science base and has received significant policy support.

Singapore was among the first jurisdictions to approve cultivated meat for sale, positioning itself as a regulatory pioneer in a field where approval pathways were undefined.

The strategic motivation is food security in a country importing almost all its food, which links biotechnology policy directly to national resilience rather than only to economic development.

What is the honest verdict on the strategy?

The strategy built a real manufacturing sector, real research infrastructure and real technical capability, at substantial public cost, over a period long enough to judge it fairly.

It did not produce a domestic biotechnology industry generating its own approved therapies, which was the most ambitious objective and the one least within any government’s control.

Judged against what industrial policy can realistically achieve rather than against its own initial rhetoric, it is a qualified success, and the qualification is instructive for any country attempting the same.

What is Fusionopolis and how does it relate?

A neighbouring research development houses physical sciences and engineering institutes, creating a co-located cluster spanning biological, physical and information sciences within a short distance.

Co-location is intended to enable interdisciplinary work, particularly where biology meets engineering and computation, which is where much current medical technology development sits.

Whether physical proximity actually produces collaboration is debated in innovation research, but it certainly reduces the friction, and the cluster has produced joint programmes across domains.

What should other countries take from this?

Build manufacturing capability first, because it is achievable, measurable and creates the industrial base that later supports research translation.

Fund research on horizons matching the science, and resist evaluating it on political timescales, since premature termination wastes everything already invested.

Be explicit about which objectives are purchasable and which are not, so that success can be assessed honestly rather than defended against expectations that were never realistic.

How does the sector recruit local talent?

Scholarship programmes, doctoral funding, industry attachments and career pathways in both research institutes and corporate laboratories aim to build a domestic scientific workforce.

Retention competes against finance, technology and medicine, all of which offer clearer career progression and higher early earnings than a research career does.

The manufacturing side has been easier to staff, since process engineering and quality roles offer stable industrial careers with clearer progression than research positions.

Frequently Asked Questions